Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease

Authors

Yan Hu, Eisai Inc.
Min Cho, Eisai Inc.
Pallavi Sachdev, Eisai Inc.
Jeffrey Dage, Indiana University
Suzanne Hendrix, Pentara Corporation
Oskar Hansson, Lund University
Randall J Bateman, Washington University School of Medicine in St. Louis
Harald Hampel, Eisai Inc.

Journal

Med

Publication Date

10-11-2024

Volume

5

Issue

10

First Page

1206

Last Page

1226

Document Type

Open Access Publication

DOI

10.1016/j.medj.2024.08.004

Rights and Permissions

Hu Y, Cho M, Sachdev P, Dage J, Hendrix S, Hansson O, Bateman RJ, Hampel H. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease. Med. 2024 Oct 11;5(10):1206-1226. doi: 10.1016/j.medj.2024.08.004. Copyright 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Hu, Yan; Cho, Min; Sachdev, Pallavi; Dage, Jeffrey; Hendrix, Suzanne; Hansson, Oskar; Bateman, Randall J; and Hampel, Harald, "Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease." Med. 5, 10. 1206 - 1226. (2024).
https://digitalcommons.wustl.edu/oa_4/4972

Department

ICTS (Institute of Clinical and Translational Sciences)